EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC

Katarina Živić iD, Ivana Boljević, Milica Nedeljković iD, Milana Matović, Radmila Janković iD, Miljana Tanić iD

Cells · 01.02.2026 · 15 (3) · 277

DOI: 10.3390/cells15030277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 01.02.2026. Verfasst von Katarina Živić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Department, Institute for Oncology and Radiology of Serbia, 11040 Belgrade, Serbia. Hauptthemen laut MEDLINE: DNA Methylation, Promoter Regions, Genetic, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja, Ministry of Education, Science, and Technological Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is a highly lethal disease. Tumors with a deficiency in the homologous recombination repair pathway (HRD) resulting from mutations in BRCA1/2 genes have a favorable response to platinum-based chemotherapy and targeted therapy with PARP inhibitors (PARPi) mediated by synthetic lethality. Promoter methylation of BRCA1/2 genes was previously associated with HRD, but little is known about whether it translates to clinical benefit. Here, we evaluated the prevalence of BRCA1/2 promoter methylation in HGSOC patients from Serbia and examined their clinicopathological characteristics and the effect on progression-free and overall survival. Using methylation-specific PCR, we screened for hypermethylation in the promoter region of BRCA1/2 genes in a cohort of 244 patients. We found fully methylated BRCA1 and BRCA2 promoter in 4.1% and 0.45% of patients, and 23.36% and 11.21% intermediately methylated cases, respectively. Full BRCA1/2 promoter methylation was significantly associated with younger age of onset (55 and 58 years, respectively) compared to BRCA1/2-mutated cases, suggestive of BRCAness phenotype. However, in the exploratory analysis of 68 patients with clinical follow-up, we did not find a strong survival advantage for BRCA1/2 methylated over BRCA1/2-intact cases, yet more moderate effects cannot be ruled out due to the cohort size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationPromoter Regions, GeneticBRCA2 ProteinBRCA1 ProteinOvarian NeoplasmsHumansFemaleMiddle AgedAdultAged

Stichwörter der Autor:innen

BRCA1/2 geneshigh-grade serous ovarian cancermethylation-specific PCRpromoter region

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Experimental Oncology Department, Institute for Oncology and Radiology of Serbia, 11040 Belgrade, Serbia.
  • Clinic for Medical Oncology, Department for Breast Tumors and Gynecologic Malignances, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
  • Medical Genomics, Cancer Biology Department, UCL Cancer Institute, University College London, London WC1E 6DD, UK.

ORCID-Profile: Katarina Živić, Milica Nedeljković, Radmila Janković, Miljana Tanić

Förderung

  • Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
  • Ministry of Education, Science, and Technological Development

Zitieren

APA

Živić, K., Boljević, I., Nedeljković, M., Matović, M., Janković, R., & Tanić, M. (2026). The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC. Cells, 15(3), 277. https://doi.org/10.3390/cells15030277

Vancouver

Živić K, Boljević I, Nedeljković M, Matović M, Janković R, Tanić M. The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC. Cells. 2026;15(3):277. doi:10.3390/cells15030277

BibTeX
@article{ivi2026,
  author = {Živić, Katarina and Boljević, Ivana and Nedeljković, Milica and Matović, Milana and Janković, Radmila and Tanić, Miljana},
  title = {The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {277},
  doi = {10.3390/cells15030277}
}
Kostenlos starten →